No primary audience was provided.
No primary audience was provided.
1. | Interpret results from new and existing HER2 testing methodologies to determine appropriate treatment decisions | 2. | Differentiate between the prognostic and predictive implications associated with HER2 positivity |
3. | Compare and contrast monoclonal antibodies and tyrosine kinase inhibitors available for the treatment of HER2-positive breast cancer | 4. | Apply evidence-based clinical trial data on new and emerging treatment strategies to ensure optimal care for patients with HER2-positive breast cancer |
5. | Monitor and manage treatment-related toxicities associated with chemotherapeutic and biologic agents used to treat HER2-positive breast cancer |
1. | Interpret results from new and existing HER2 testing methodologies to determine appropriate treatment decisions |
2. | Differentiate between the prognostic and predictive implications associated with HER2 positivity |
3. | Compare and contrast monoclonal antibodies and tyrosine kinase inhibitors available for the treatment of HER2-positive breast cancer |
4. | Apply evidence-based clinical trial data on new and emerging treatment strategies to ensure optimal care for patients with HER2-positive breast cancer |
5. | Monitor and manage treatment-related toxicities associated with chemotherapeutic and biologic agents used to treat HER2-positive breast cancer |